Author's response to reviews

Title: The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

Authors:

Gabriele Greve (gabriele.greve@uniklinik-freiburg.de)
Insa Schiffmann (insa.schiffmann@uniklinik-freiburg.de)
Dietmar Pfeifer (dietmar.pfeifer@uniklinik-freiburg.de)
Milena Pantic (milena.pantic@uniklinik-freiburg.de)
Julia Schüler (julia.schueler@oncotest.de)
Michael Lübbert (michael.luebbert@uniklinik-freiburg.de)

Version: 4 Date: 3 November 2015

Author's response to reviews: see over
Dear Dr. Solera,

after we performed additional experimentation and improvements of different Figures (as suggested by the two reviewers), one of them (referee #2), after re-reviewing the manuscript, appreciated the additional experiments but noted that both the Results and Discussion sections still included many redundancies and could significantly be shortened. Actually, he had already remarked this during the first review. We apologize that within the time constraints of conducting several series of additional experiments, we had neglected to also perform these improvements. Therefore we now thoroughly shortened and "streamlined" particularly the Results and Discussion sections, improved the English language, and are grateful to the reviewer for again pointing out these deficits.

Specifically, the Results section is now 3 pages long (before: 4 1/2), the Discussion was reduced half a page. We are happy to provide a marked copy documenting how and where the text was shortened.

We hope that in its current form, our manuscript may be found acceptable for publication.

Sincerely yours

Michael Lübbert, MD PhD
Dept. of Medicine, Div. Hematology, Oncology and SCT
University of Freiburg Medical Center
Hugstetter Str. 55
D-79106 Freiburg, Germany
phone 49-761-270-32790
FAX 49-761-270-36970